Endometriosis Patients Undergoing Quinagolide Treatment

Learn more about:
Related Clinical Trial
Administration of Kisspeptin to Subjects With Reproductive Disorders The Luveris In Vitro Fertilization Trial A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Pituitary Function and Spontaneous Intracranial Hypotension Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Aripiprazole and Prolactin Study Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Characterization of Macroprolactinemia Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Endometriosis Patients Undergoing Quinagolide Treatment Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Hyperprolactinemia and Adrenal Steroidogenesis Administration of Kisspeptin in Patients With Hyperprolactinemia Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Brief Title

Endometriosis Patients Undergoing Quinagolide Treatment

Official Title

Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Brief Summary

      Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies,
      diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic
      lesions.
    


Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

observation of three month treatment with Quinagolida in endometriosis patients


Condition

Hyperprolactinemia

Intervention

ENDOMETRIAL BIOPSY


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

5

Start Date

February 2008

Completion Date

May 2008

Primary Completion Date

April 2008

Eligibility Criteria

        Inclusion Criteria:

          -  Hyperprolactinemia

          -  Unexplained infertility

          -  Endometriosis
      

Gender

Female

Ages

18 Years - 37 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Spain

Location Countries

Spain

Administrative Informations


NCT ID

NCT00625950

Organization ID

VLC-AP-10208-208-1



Study Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA


Study Sponsor

, , 


Verification Date

January 2009